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ABSTRACT 
Background: Good adherence to ART prolongs survival and improves quality of life 
in people living with HIV/AIDS. Adherence is commonly assessed using self-reported 
measures, but these tend to over-estimate adherence. Viral load testing is the gold 
standard for measuring ART adherence but it is unaffordable in resource limited 
settings. Therefore, the aims of this small sub-study were to validate self-reported 
measures of adherence and to find factors associated with adherence to ART in 
Jinja, Uganda.  
Methods: This study was a secondary analysis of data collected from a cluster 
randomized equivalence trial which was carried out to compare facility based ART 
care versus home based care. In the main study, 1453 participants aged 18 and 
above were enrolled. A total of 1276 men and women qualified for this sub-study.  
Receiver operating characteristic (ROC) was computed to see how well two self-
reported measures of adherence predicted virological failure. The two self-reported 
measures were firstly a visual analogue score (VAS) where participants rated the 
number of doses that they had taken in the past month on a scale from 0 (meaning 
no ART taken) to 100 (meaning that all required doses had been taken) and 
secondly an adherence score based on the number of pills missed in the three days 
before the visit.  Logistic regression models were fitted with survey estimator to find 
factors associated with virological failure. Tobit models were fitted to find factors 
associated with self-reported adherence measures, since these were restricted to 
the range of 0-100% and censored.  We then compared associated factors among 
the three different outcome measures. 
Results: There were 914 women and 362 men in this study. Home based care had 
larger number of patients (754) than facility based care (522). The median age of the 
patients was 38 years (IQR 32.0-44.0). Most of the participants were either married 
(518) or single (456). The majority of the trial participants had primary school 
education (n=713) and very few achieved tertiary education. A large number of 
participants had CD4 cell counts of less than 50 cells/mm3 (n=351), and very few of 
the patients in the trial had CD4 counts greater than 200 cells/mm3. The median CD4 
count of the study participants was 116 cells / mm3 (IQR 43.0-167.0). A very large 
number of the patients were either in WHO clinical stage II or III (Stage II: n= 595; 
Stage III: n=577). A total of n=1079 (84.56%) and n=197 (13.44%) participants had 
no virological failure and failure respectively. The ROC methods showed that the 
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self-reported adherence measures estimated virological failure with a sensitivity that 
ranged between 35-65%. Female patients had lower odds of experiencing virological 
failure (odds ratio: 0.7; 95% CI: 0.485, 0.968; p=0.033). The odds of virological 
failure decreased with each one year increase in age (OR: 0.95; 95% CI: 0.928, 
0.979; p=0.001). Participants who found adherence reminders very useful were less 
likely to experience virological failure (P=0.001). 
Conclusion:  This study show that self-reported measures are not good predictors 
of ART adherence since approximately only a half of the Jinja participants with 
virological failure were predicted by such measures. None of the factors associated 
with virological failure was also associated with both of the self-reported adherence 
measures. Viral load testing should be encouraged in place of self-reported 
adherence measures to ART. In addition, alternative methods of measuring 
adherence such as electronic medication monitoring, pharmacy refills and drug level 
detection should be investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGEMENTS 
My sincere acknowledgement goes to the Wits University for awarding financial 
assistance during the course of the study. My thanks also extend to the Human 
Health Research Ethics Committee for granting ethical clearance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
TABLE OF CONTENTS 
Contents Page number 
Declaration II 
Abstract III-IV 
Acknowledgment V 
List of figures VII 
List of tables VIII 
Nomenclatures IX 
1. Introduction 1 
1.1. Background 1 
1.2. Literature review 3 
1.3. Problem statement 7 
1.4. Justification 7 
1.5. Research questions 8 
1.6. Aims and Objectives 8-9 
2. Methods 10 
2.1. Study description 10 
2.1.1. Study design  10 
2.1.2. Study settings 10 
2.1.3. Study population  10 
2.2. Intervention 12 
2.3. Exposures and outcomes/possible confounders 12 
2.4. Selection of study population 13 
2.4.1. Eligibility criteria 13 
2.4.2. Sampling 13 
2.4.3. Randomization 13 
2.5. Study procedures 13 
2.5.1. Procedures at enrolment 13 
2.5.2. Follow-ups 13 
2.6. Measurements of outcomes 14-15 
2.7. Laboratory methods 15 
2.8. Sample size calculation 15 
2.9. Data management 16 
3. Ethical considerations 16 
4. Data analysis 17-20 
5. Results 21-39 
6. Discussion 40-46 
7. References 47-54 
8. Appendices 55 
8.1. Plagiarism declaration report 55 
8.2. Ethics clearance certificate 56 
8.3. Adherence questionnaire 57-75 
 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
 
Figure 1: COHORT chart for cluster randomised trial 
Figure 2: Histogram showing distribution of adherence score based on visual 
analogue scale (%). 
Figure 3: Highlights the excess of participants with adherence score based on visual 
analogue scale measurement.   
Figure 4: Histogram showing distribution of adherence score based on number of 
pills missed (%) 
Figure 5: Highlights the excess of participants with adherence score based on the 
number of pills missed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF TABLES 
 
Table 1: Socio-demographic and clinical characteristics by study arm  
Table 2: Comparison of clinical characteristics of 1276 patients included in this study 
and 177 enrolled in the main trial but excluded from this secondary analysis 
Table 3: Distribution of adherence measurement scores according to virological 
failure status  
Table 4: Description of outcome measures 
Table 5a: ROC analysis for adherence visual analogue score  
Table 5b: ROC analysis for adherence based on number of pills missed 
Table 6:  Assessment of the association between factors and virological failure: 
Univariable model  
Table 7: Factors that were significantly associated and virological failure: 
Multivariable model 
Table 8: Odds ratios for association of factors with virological failure: Final model 
Table 9: Assessment of the association between factors and VAS: Univariable model  
Table 10: Factors significantly associated with VAS: Multivariable model 
Table 11: Prediction of VAS using factors associated with virological failure and 
factors associated with VAS: Final model analysis 
Table 12:  Assessment of the association between factors and adherence based on 
number of pills missed: Univariable model 
Table 13: Factors that were significantly associated with adherence based on 
number of pills missed: Multivariable model 
Table 14: Prediction of adherence based on number of pills missed using factors 
associated with virological failure and factors associated with VAS: Final model 
analysis 
Table 15: Comparison between predictors of virological failure and self-reported 
adherence 
 
 
 
 
 
 
ix 
 
LIST OF ACRONYMS AND ABBREVIATIONS 
 
HIV: Human Immunodeficiency Virus 
  
AIDS: Acquired Immune Deficiency Syndrome 
  
ART: Antiretroviral Therapy 
  
ARV: Antiretroviral drug 
  
WHO: World Health Organization 
  
TASO: The AIDS Support Organization (Uganda) 
  
UNAIDS: United Nations Programme on HIV/Acquired Immuno-deficiency Syndrome 
  
UAC: Uganda Aids Commission 
ABC: Abstinence, Be faithful, Use a Condom 
 
 
 
 
 
1 
 
1. INTRODUCTION 
1.1. Background: 
Globally, HIV/AIDS remains a major cause of mortality and morbidity. An estimated 
36.9 million people are living with HIV/AIDS and around 2 million were newly infected 
and about 1.2 million died globally due to the epidemic in 2015 (UNAIDS, 2016).  
The greatest burden of the disease is found in sub-Saharan Africa where almost 
25.8 million (uncertainty interval 24.0 million - 28.7 million) are living with HIV/AIDS 
and the region is having 66% of all new infections in the world.  In Uganda, an 
estimated 1.5 million are living with the virus; adults aged 15 and over account for 
about 1.4 million of the HIV positive people in Uganda, with a prevalence of  about 
7.1% by the end of 2014 (UAC, 2014).  Nevertheless, sub-Saharan Africa has 
registered some improvement in HIV/AIDS management and Uganda is not an 
exception. For example, new HIV infections have remarkably reduced by 41% 
between 2000 and 2014.  Deaths caused by AIDS fell by 48% between 2004 and 
2014 in sub-Saharan Africa (UNAIDS, 2016). In Uganda, according to the HIV 
country progress report, new HIV infections declined considerably as did HIV/AIDS 
related deaths. New HIV infections decreased to about 95,000 in 2014 (down from 
160,000 in 2010) and HIV/AIDS related deaths also dropped from 67,000 in 2010 to 
31,000 in 2014 (UAC, 2014).  Despite this, the East African nation is still regarded as 
a high burden country with a high number of people living with HIV/AIDS and a 
relatively large number of new infections. 
In order to continue with the downward trend of new HIV infections and HIV/AIDS 
related deaths, UNAIDS in 2014 introduced a “Fast Track Strategy” which aims to 
step up the response to HIV in low and middle income countries and end the disease 
by the year 2020 (UNAIDS, 2014). The strategy set the “90 90 90” targets which 
stands for “90% of people living with HIV should know their status”, “90% of people 
who know they are HIV positive should have access to treatment” and “90% of 
people on treatment should have achieved viral load suppression”. For its part, 
Uganda has been using a more pragmatic approach which emphasizes the 
“Abstinence, Be faithful and always use a Condom” (ABC) slogan.  The ABC 
approach and a system of voluntary counselling and testing and billboards 
awareness was promoted by the Ugandan government to prevent spread of HIV 
(UAC, 2014). The approach in Uganda led to a dramatic drop in HIV/AIDS infection 
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rates (Stoneburner and Low-Beer, 2004, Hearst and Chen, 2004).  The billboards 
raising awareness of HIV and promoting voluntary counselling and testing led to 
people being more openly aware of the epidemic and had a positive impact as more 
people living with HIV/AIDS enrolled to receive ART. To achieve viral load 
suppression, the country took a more combative treatment effort by adopting the 
2013 WHO guidelines. ART became available in the public sector from 2003 
onwards. Access to ART in Uganda has increased up to about 751,000 in 2014. ART 
roll out has importantly enabled an estimated 76% of the people in Africa to achieve 
virological suppression  (UAC, 2014).  
Since it has been established that viral load suppression can be achieved by use of 
antiretroviral drugs, much emphasis within HIV/AIDS programmes has been on the 
roll out of ART. The need to monitor adherence to ART has not been given much-
needed attention. That is why the government of Uganda has placed ART adherence 
and retention in care on the agenda as part of the planned remedial action for 2014 
and 2015 (UAC, 2014). Good adherence to ART is important if we are to maintain 
the downward trend of HIV related deaths through slowing disease progression. In 
addition good adherence reduces the risk of HIV transmission through suppressing 
viral load. One way of measuring adherence to ART is by viral load testing. In 2013, 
WHO recommended routine viral load testing with viral loads tested 6 months after 
starting treatment and thereafter once a year to see if the treatment is working, to 
identify need for possible second-line drugs and above all, to distinguish between 
treatment failure and adherence failures (WHO, 2016).  The WHO recommends that 
every patient must at least achieve an adherence score of 95% if viral resistance to 
the medication is to be prevented (Stone et al., 2001). According to Remor (2013) 
there are two different ways of measuring adherence to medication. For example, 
the direct methods which include examination of active drug in blood, and the 
indirect methods including clinical assessment, pill count and self-report. 
Self-reported measures are defined by questions involving missed doses or by a 
visual analogue score where a mark is made on a line drawn from 0 to 100%, 
relating to the percentage of HIV drugs  consumed and other assessment methods 
containing reasons for non-adherence (Giordano et al., 2004, Walsh et al., 1998). 
However, self-report has some shortcomings too; one of them is that it could be 
subjective as a patient may not want to be seen to be disobeying medical 
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recommendations. For a self-report based method of ART adherence to be reliable, 
feasible and valid, other approaches need to be employed to validate it. Therefore 
we conducted a validation of 2 self-reported measures (visual analogue scale and a 
measure based on the number of pills missed in the past 3 days) by comparing them 
to the results from viral load testing, and also investigating if they can be predicted 
using the same risk factors. While self-reported measures have not been fully 
evaluated to date, the relationship with plasma HIV ribonucleic acid (RNA) has been 
established (Simoni et al., 2006b). Virological failure is established using laboratory 
tests as a direct measure of effectiveness and outcome of ART adherence.  
1.2. Literature Review:  
 
ART adherence studies in Africa have mainly been carried out among adults. 
Adherence is usually measured as the percentage of required doses taken over a 
specified period of time, ranging from 0 - 100% (Miller and Hays, 2000, Catz et al., 
2000). Studies in Africa found that 77% of individuals on ART achieved the WHO 
target of adherence (Mills et al., 2006b). There are many ways of measuring 
adherence.  The best objective measure of adherence is HIV viral load testing, but 
its use is limited due to high costs (Bangsberg, 2008, Bova et al., 2005). In resource 
limited settings pharmacy adherence measures (PAM) which include pharmacy pill 
count, pill pick-up and medication or drug possession ratio are recommended since 
they are of a relatively lower cost and have been found to predict virological failure 
(Meyer et al., 2011). Self-reported measures are therefore the most widely used 
methods today because of low cost and ease of operation, which avoids the use of 
sophisticated equipment; in addition it is possible to validate these methods 
(Hawkshead and Krousel-Wood, 2007, Paterson et al., 2002). The objective is to see 
whether either (or both) of the self-reported adherence measures can be used as a 
proxy measure for virological failure However, past studies have found shortcomings 
with self-reported methods of adherence. One study indicated that the time frame 
used for recall could affect accuracy of the recall (Paterson et al., 2002). In order to 
get a more valid self-reported measure of adherence, it is important that self-
reported recall periods are taken into consideration, since it is human nature to 
remember things that happened yesterday better than things that happened the day 
before yesterday. A systematic review found self-report recall periods to be 
associated with HIV-1 RNA viral load and CD4 count (Simoni et al., 2006a). Further 
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studies have also confirmed that self-reported adherence measures tend to 
exaggerate good adherence, since they reflect short term adherence that may give 
an over-estimate of overall adherence (Arnsten et al., 2001b, Liu et al., 2001, 
Wagner et al., 2004). One other disadvantage of self-reported measures may be that 
the respondent may give a response that he or she thinks the interviewer would want 
to hear.  
Some of the possible factors contributing to poor adherence in Africa are related to 
socioeconomic factors, while others are behavioural. Various factors have been 
found to be associated with adherence to ART. Personal adherence reminders have 
been one of the most important predictors of adherence in previous studies. For 
instance, a study conducted in Laos in Asia, revealed that the major contributor to 
non-adherence to ART was forgetfulness (62.2% of 346 participants) (Hansana et 
al., 2013). Similar results were also found in Africa. For example, in Uganda, a study 
reported that 97% and 93% of the participants did not miss their doses and 
appointment respectively. The study also found that travel and forgetfulness were 
the reason for missing doses (Shumba et al., 2013).  Similar findings were confirmed 
in Ethiopia where factors associated with poor adherence were also forgetfulness 
and travelling (Mitiku et al., 2013). Studies on the relationship between 
socioeconomic factors and ART adherence in Uganda are limited and it is not clear 
what effect these factors have on ART adherence. Available studies from middle and 
low income countries reported that income and level of education were significantly 
and positively associated with level of ART adherence in 15 and 10 studies (Peltzer 
and Pengpid, 2013).  
When comparing achievement of ART adherence levels between low income 
regions and high income regions, (in this instance Africa and North America),  a 
study showed that Africa had relatively higher adherence rates with about 20% more 
patients achieving over 80% adherence (Mills et al., 2006b). A few studies have 
reported on factors that are related to ART adherence in resource limited settings.  
Poor adherence was associated with age, in particular for young and old participants 
and also with missing clinic appointments in Tanzania; this study highlighted the 
importance of creating an adherence reminder protocol for clinic appointments, as 
studies elsewhere also reported forgetfulness as one of the predictors of poor 
adherence (Watt et al., 2010). Various factors have been found to contribute to poor 
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ART adherence, including cost, transport, stigmatization and lack of control over 
household materials (Braitstein et al., 2008, Gilks et al., 2006, Snow, 2009). Studies 
report that among many factors affecting adherence, demographic characteristics 
such as gender are important (Stone et al., 2001). Other studies indicate that factors 
such as side effects, pill burden, time on ART, and doctor-patient relationship may 
affect adherence (Schneider et al., 2004). A study found that 72% of patients at 12 
and 24 months of ART had 75% and 72% undetectable HIV RNA and virological 
failure was associated with poor adherence, general clinical symptoms associated 
with WHO stage of the disease, and lower weight (Ahoua et al., 2009). Some factors 
affecting adherence may be similar across countries, while others may be country 
specific (Sabin et al., 2008, Weidle et al., 2006). 
When reviewing literature to find out which self-reported adherence measures 
currently available are acceptable to patients, valid and reliable, the visual analogue 
scale and percentage of pills missed were identified. A visual analogue scale was 
found to be much easier to use than reporting the number of doses or pills missed 
(Garfield et al., 2011). In Europe, a higher visual analogue score was found to 
correspond with viral suppression with statistically significant association 
(Chkhartishvili et al., 2014). It is important to assess these 2 self-reported measures 
in a Ugandan context. Adherence to ART is widely regarded as one of the most 
important predictors of survival for people living with HIV/AIDS (Garcia de Olalla et 
al., 2002). Good ART adherence of 95% or more decreases the chances of 
opportunistic infections and reduces viral load (Hogg et al., 1999). In contrast, poor 
adherence leads to development of HIV viral resistance which quickens the 
development of HIV to AIDS, and decreases quality of life (Bangsberg et al., 2001). 
Strict adherence is difficult to maintain given the rapid replication rate of the virus, 
the complex nature of the ARV regimens and the combination of short and long term 
toxic effects (Thompson et al., 2012), all of which pose a challenge for individuals on 
ART. Nonetheless, patients must try to achieve the required level of ART adherence.  
There is no universal method of self-report with many researchers using different 
periods of recall to assess adherence (Lu et al., 2008). The major challenges related 
to self-reported measures of adherence are concerns about their validity due to the 
potential for social desirability and memory bias. Many self-report methods such as 
response scale formats and  time interval for recall are commonly used (Garfield et 
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al., 2011). A systematic review in 2006 suggested that measuring ART adherence 
using quantitative methods such as viral load was even more important in Africa than 
in the United States of America (Mills et al., 2006b). However the review fails to take 
into consideration the fact that sub Saharan Africa is a resource limited setting 
(Nahman et al., 2009). Self-reported measures of adherence therefore are the only 
methods available in many poor settings. Increased roll out of ART cannot be 
achieved fully without improving health systems which could emphasize retention, 
adherence and medication protocol compliance.  
Few studies have empirical evidence to validate self-reported measures of ART 
adherence. Thus we evaluated two self-reported measures of adherence to ART and 
also investigated factors associated with adherence. This study used secondary data 
analysis of a cluster randomised trial in which participants were randomised by 
cluster to receive either home based ART or facility based ART in Jinja, South 
Eastern Uganda (Amuron et al., 2007, Jaffar et al., 2010). The secondary analysis 
presented here compares two self-reported measures of adherence by assessing 
how well they predict virological failure.   
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1.3. Problem statement:  
While much emphasis has been placed on scaling up ART, the need to retain those 
already on treatment and to improve adherence has not been fully addressed in 
Ugandan government plans (Knodel et al., 2010). If we are to see suitable outcomes 
of scaling up ART as part of a universal effort towards eradicating the HIV epidemic, 
a measure of adherence should be part of HIV treatment policies.  Viral load testing 
is the best measure of adherence, however Africa is a resource limited setting and 
many countries cannot afford routine viral load testing. Therefore there is a need for 
alternative measures of adherence, and self-reported measures are the cheapest 
available. One problem that has hindered the progress of ART adherence is the 
absence of a standard measure for self-reported adherence. As noted above, self-
reported measures tend to over-estimate adherence. These measures also depend 
on the recall of participants, while the questions asked may not be properly 
communicated to the participants as the questionnaire may contain too many 
medical terms and recommendations (DiMatteo et al., 1992, Chesney et al., 2000). 
 
1.4. Justification: 
Viral load monitoring in most settings across Africa is unaffordable and requires 
sophisticated equipment (WHO, 2006). The clinically positive effects of ART in 
suppressing HIV virus and prolonging survival of people living with the infection are 
well documented (Kredo et al., 2009, Lohse et al., 2007, Vergidis et al., 2009), 
especially for patients who follow proper medication protocols and adhere to 
treatment modalities. Thus it is important that we evaluate self-reported measures of 
adherence. Finding a standard self-reported method is very important so that it can 
be used in place of viral load testing to monitor ART adherence. Self-reported 
measures may reveal risk factors for poor adherence to ART, including social, 
situational and behavioural factors and factors related to medicinal use (Hawkshead 
and Krousel-Wood, 2007). Many of these factors are particularly relevant in resource 
limited settings. The need to address these factors remains very important in 
improving ART adherence. This study will aid in strengthening health systems in 
HIV/AIDS treatment care and adherence. 
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1.5. Research questions  
How valid are two self-reported measures of adherence to ART (visual ART score 
and number of pills missed) and what factors are associated with adherence to 
ART?  
1.6. Aims and objectives  
The aims of the study were to assess the two self-reported measures of adherence 
to ART and to identify factors associated with adherence to ART from a cluster 
randomised equivalence trial carried out in Jinja, South Eastern Uganda, from 2005 
to 2009. 
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Objectives 
The major objectives of this secondary analysis using data from a cluster 
randomised trial carried out from 2005 to 2009 in South East Uganda were the 
following: 
1. To compare two self-reported measures of ART adherence by seeing how 
well each predicts virological failure. 
2. To investigate factors associated with:  
      a) Virological failure 
      b) Adherence as defined by the two self-reported measurement scores 
3. To compare which factors are associated with virological failure and also with 
both of the adherence measure (s).  
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2. METHODS 
2.1. Study description 
2.1.1. Study design:  
This was a secondary data analysis of a cluster randomised equivalence trial on  
virological failure comparing facility based ART to home based ART care; 44 
geographical clusters were randomized, with randomisation stratified by location and 
distance to the clinic in Jinja, south eastern Uganda (Jaffar et al., 2010). This 
secondary data analysis adopted the same study design. 
2.1.2. Study setting/site: 
The main trial was carried out in Jinja district, South Eastern Uganda. The facility 
based care was delivered at “The AIDS Support Organisation” (TASO), a clinic in 
Jinja town. TASO is the largest provider of ART in Uganda.  
2.1.3. Study population 
Participants were recruited from TASO clients who either had a “CD4 cell count less 
than 200 cells/µl or had WHO stage IV or late stage III disease and who initiated 
ART between 15 February 2005 and 19 December 2006” (Jaffar et al., 2010). A total 
of 1453 HIV-infected women and men aged 18 years or older were enrolled for the 
primary study. We included all participants who could potentially experience 
virological failure. Since virological failure was only measured from the 12 month visit 
onwards, this meant that we only included participants who had a visit at 12 months 
or later. A total of 1276 patients from the total number of the primary study qualified 
for this secondary study because they were observed at month 12 or beyond. See 
figure 1 for the CONSORT diagram for the main trial. In the CONSORT diagram, the 
number of patients analysed was lower than the one we used in this study because 
of different eligibility criteria for this secondary analysis. We decided to adjust the 
number of patients for analysis in the diagram for consistency.  
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Figure 1: Jaffar et al. (2010). CONSORT diagram for cluster randomised trial 
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2.2. Intervention:   
Participants were randomised by cluster to either receive hospital based ART care or   
home based ART care. 
2.3. Main exposures, potential confounders and outcomes for each 
objective 
Objective one: Comparing two self-reported measures of ART adherence by seeing 
how well each predicts virological failure. For this objective, adherence is an 
exposure but for objective 2b it is an outcome.  
Outcome: Virological failure.  
Exposures: Visual analogue score and number of pills missed (both exposures are 
measured as a percentage). 
Objective 2a: Finding factors associated with virological failure. 
Outcome: Virological failure.   
Exposures: WHO stage for HIV, means of transport, usefulness of adherence 
reminders, CD4 cell counts, BMI, study arm and time taken to reach clinic. 
Potential confounders: Education, sex, marital status and age. 
Objective 2b Finding factors associated with self-reported measures (adherence 
measures). Only factors that were found to be statistically significantly associated 
with virological failure were considered as candidate explanatory variables for the 
models of the two self-reported measures of adherence. 
Outcomes: The “visual analogue score” and the adherence score using “number of 
pills missed” (self-reported adherence measures).  
Exposures: WHO stage for HIV, means of transport, usefulness of adherence 
reminders, CD4 cell counts, BMI, study arm and time taken to reach clinic. 
Potential confounders: Education, sex, marital status and age. 
Objective 3: Comparing factors associated with both virological failure and self-
reported adherence measures scores 
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This objective involves a comparison of the findings for objective 2a and objective 2b 
so does not have its own outcome, exposures and potential confounders.   
2.4. Selection of study population 
2.4.1. Eligibility criteria  
ART treatment requirements proposed by the Ministry of Health in Uganda were 
used to inform the inclusion criteria for the primary study. According to the 
guidelines, all people with HIV were eligible to start ART if they satisfied either of the 
following criteria. 
1. WHO stage IV or late stage III disease  
2. A CD4 cell count of less than 200 cells per microliter.  
The inclusion criterion for this secondary study was to include all those participants 
who were followed up at month 12 or beyond.   
2.4.2. Sampling  
A total of 1453 participants were enrolled for the primary study.  A total of 1276 
participants in the primary study with at least one year of follow-up were included in 
this secondary analysis. All participants who satisfied the eligibility criteria for this 
secondary analysis were included. Since the eligibility criteria for this secondary 
analysis was different from that of the main paper, the number of patients for 
analysis in the CONSORT diagram was lower than the one we used in this study. In 
order to achieve some consistency, we adjusted the number of patients for analysis 
in the CONSORT diagram to match 1276, the number we used in this study.  
2.4.3. Randomisation  
A concealed box with cards containing either home based or facility based care were 
randomly drawn by two patient representatives, a TASO medical officer, TASO 
counsellor, and TASO field officer for each community, in order to determine the arm 
to which the community would be allocated (Jaffar et al., 2010).  
2.5. Study procedures 
2.5.1. Procedures at enrolment 
Eligibility criteria were employed to screen patients for ART starting in August 2004 
with enrolment which ended in 2006.  Patients starting ART for the first time and 
were 18 years and older were allowed to join the study. All patients provided 
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informed consent. The right to autonomy, that is to say to refuse or withdraw from 
the trial at any time was conveyed to the participants. Questionnaires were written in 
English and translated into Luganda.  Special persons not affiliated with the research 
were employed to help in translation. Luganda is a commonly spoken language in 
South Eastern Uganda. No financial incentives were used to motivate people to join 
the trial.  
2.5.1. Follow-up  
Patients in both arms of the study were followed up for interview at 2 months and 
again 6 months.  From the main paper, enrolment began on 15 February 2005 and 
ended 19 December 2006. Thereafter they were followed up every six months. 
Follow-up continued until 31 January 2009, so participants were in the trial for 2-3 
years. For follow-up visits, if a patient missed an appointment, the fieldworker went 
to his/her home, if the participant was not at home, the fieldworker left a message 
that the patient should come to the TASO clinic in Jinja. Under normal 
circumstances, patients who missed a follow-up visit were followed-up by research 
fieldworkers, and reminded to attend clinic and their consent was taken for possible 
consideration of home based care in case a participant was unable to make it to the 
clinic on the day of follow–up or review. Clinic visits were required by all patients 
from both arms for routine clinical check-ups by medical officers. The home based 
participants had 6-monthly clinic visits while the clinic based participants had monthly 
clinic visits. ART was dispensed on a monthly basis to both home based care and 
facility based care participants.   
2.5.2. Measurement of variables 
 Virological failure 
A viral load test result was used to define virological failure as a binary variable with 
0 denoting no virological failure and 1 denoting virological failure. In the primary 
study, virological failure and associated time of failure was only assessed from 12 
months onwards. If all viral load measurements for a subject from month 12 onwards 
were below 500 copies / ml, then the subject was deemed not to have failed. If a viral 
load measurement exceeded 1,000 copies per ml then the subject was considered a 
failure at the first visit at which this occurred. If the viral load was between 500 and 
1,000 copies per ml at any visit, then the subject was considered a failure at that visit 
if at the next visit the viral load was 500 copies or higher. If at the second visit the 
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viral load was below 500 copies per ml, then the subject was not considered a 
failure. If the final viral load was between 500 and 1000 copies per ml, then a 
confirmatory viral load was done. Viral load was measured every six months, but 
virological failure was only assessed from month 12 onwards, as the viral load could 
take longer than six months after the initiation of ART to reach undetectable levels.  
Adherence defined by visual analogue scale (VAS) 
The visual analogue score was defined as the proportion of doses that a participant 
had taken and ranged between 0% (if the participant had not taken any drug) to 
100% (if the participant had taken all the required doses). The participant rated his or 
her adherence at each adherence visit by marking a point on a line going from 0 to 
100 (see appendix 8.3 for the main trial adherence questionnaire). For the analysis 
we used the mean value of the score calculated over all the adherence visits for 
each study participant.  For those participants who experienced virological failure, 
data was included up to and including the visit at which the participant experienced 
the failure meaning that if a patient missed a visit, the adherence was not included in 
the adherence score. Also if an appointment or visit was missed from either arm, an 
effort was made to ensure that antiretroviral drugs were delivered to the patient. This 
was done by follow up at home by any of the trial team members especially if 
patients had consented to home visits.  
Adherence based on number of pills missed 
The adherence based on number of pills missed was calculated as a proportion by 
dividing the number of pills missed in the last 3 days by the total number of pills that 
should have been taken over the last three days, excluding the day of the visit (see 
appendix 8.3 for the main trial adherence questionnaire). The calculation was done 
at each visit and the mean score over all adherence visits for each participant was 
used. This was calculated as number of pills missed by the participant in the last 3 
days excluding today as adherence percentage score.  The higher score 
corresponds to fewer pills missed. 
    
3 X number of pills taken every day−Number of pills missed over last 3 days
3 X number of pills taken every day
 X 100% 
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For those participants who experienced virological failure, data was included up to 
and including the visit at which the participants experienced the failure. Adherence 
measurement was taken every 6 months after ART roll out.  
2.6. Laboratory methods  
The TASO staff monitored CD4 cell counts every 6 months. TriTEST (Becton-
Dickenson, Franklin Lakes, NJ, USA) reagents were used to measure CD4 cells 
according to an in-house dual-platform protocol and MultiSET and Attractors 
software (version 2.2) with a FACScan flow cytometer (Becton-Dickenson, Franklin 
Lakes, NJ, USA). In laboratory testing of RNA viral load, the storage temperature for 
the plasma was at – 80oC. HIV-I RNA test was carried using VERSANT RNA 3.0 
(Bayer, Bayer Healthcare, NY, and USA) assay “(with a lower limit of detection of 50 
copies per mL)” for samples drawn at baseline.  The Amplicor MONITOR 1.5 
(Roche, Roche Molecular Systems, NJ, and USA) was used to test other samples 
(400 per copies per mL). The laboratory tests showed strong agreement between the 
results of the two assays (Jaffar et al., 2010).  
2.7. Sample size considerations  
The sample size for the primary Jinja Cluster Randomized Trial was calculated using 
the assumption that virological failure rate for participants in the ART facility based 
care would be 10 per 100 person-years at risk. A sample size of 1200 participants 
from 20 clusters per group gave over 95% power to show equivalence in virological 
failure in the two arms, with the assumption that the between cluster coefficient of 
variation was 0.2.   A total of 4560 participants was screened, 2636 participants 
qualified for ART. From the 2636, 1889 (41%) were enrolled for ART. The remaining 
59% did not return to clinic.  A total of 1488 patients were started on ART, however, 
11 patients didn’t meet one of the eligibility criteria for the trial; a total of 1477 
remained and were requested to join the trial, but 24 refused so finally 1453 were 
recruited to the study (Jaffar et al., 2010). This secondary study used a sample size 
of 1276 participants who were still in the trial at month 12 onwards, so that virological 
failure could be assessed. 
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2.8. Data management 
In the primary study, all data were doubled entered to ensure consistency. Before 
performing the secondary analysis, the data were inspected for duplicates and 
obvious discrepancies. Missing values were checked. For every participant, a 
summary measure of adherence was obtained using all the adherence data. This 
was done separately for each of the two self-reported measures of adherence. 
Confidentiality and privacy of all participants was ensured by removing all identifiers 
and remaining with a coded study Identity number. All data cleaning and analysis 
was done using Stata 13.1 
 
3. ETHICAL CONSIDERATION 
Ethical approval for the primary study was acquired from the London School of 
Hygiene and Tropical Medicine, the Uganda Virus Research Institute and the 
Uganda National Council of Science and Technology. A data sharing agreement was 
obtained from the Uganda Virus Research Institute. Ethics clearance for this 
secondary study was obtained from Human Research Ethics committee (HREC), 
Faculty of Health Science, University of the Witwatersrand, Johannesburg. 
 
4. DATA ANALYSIS 
Explanatory variables: The categorical variables included study arm, coded as 1 for 
facility-based care and 2 for home-based care. Data on clinical, socio-demographic 
and behavioural characteristics were considered as potential risk factors for ART 
adherence. Socio-demographic factors included age, sex, educational status and 
marital status. Sex was coded as 1 for males and 2 for females. Marital status was 
coded as 1-4, (1: single, 2: married, 3: divorced and 4: widowed). Educational status 
coded as 1- 4, with 1: no formal education, 2: Primary education, 3: secondary 
education and 4 was tertiary education.  
Clinical factors included BMI, CD4 and WHO stages. HIV WHO stage was coded as 
I-IV, with I: asymptomatic, II: Moderate weight loss and respiratory infections, III: 
Severe weight loss and unexplained persistent fever and diarrhoea, IV: HIV 
syndrome, pneumonia and meningitis (WHO, 2005). CD4 count x 106/l, and CD4 
group106/l coded as I-5, 1: <50, 2: 50- 99, 3: 100-149, 4: 150-199, 5: >=200.  
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Many participants’ adherence to ART might depend on behavioural characteristics; 
therefore behavioural characteristics included usefulness of adherence reminders, 
the form of transport used to reach the clinic and the time taken to reach clinic. The 
question on the usefulness of adherence reminders was included, as it is used in the 
tools of many health care providers who are trying to improve adherence. These 
tools include medicine companion and field officers who monitor patients using a 
check list as part of the trial procedures. The usefulness of the adherence reminder 
was coded as 1-3 with 1: very useful, 2: moderately useful and 3 as not useful (see 
appendix 8.3 for the main trial adherence questionnaire). We also believed that in 
this resource limited setting, the form of transport used to get to the clinics might 
have influenced ART adherence. The main form of transport was coded as 1 -5, with 
1: walk, 2: public taxi, 3: Motorcycle taxi (“Boda-boda”), 4: Bicycle taxi (“Boda-boda”) 
and 5 were other forms of transport.  Continuous variables included CD4 count x 
106/l, age measured in years, time taken to reach clinic in hours and body mass 
index (kg/m2). 
Statistical analysis  
Descriptive analysis 
A summary of the study population was given.  Description of social, demographic 
and clinic characteristics of the participants stratified by the trial arm was illustrated. 
We also gave comparison of demographic and clinic characteristics of participants 
who qualified for this secondary analysis versus those who did not. For continuous 
variables, summaries consisting of medians and inter-quartile ranges were given 
stratified by study arm.  
Analysis to address the objectives 
Objective one: In order to assess which self-reported adherence measure is a 
better predictor of virological failure, we fitted separate univariable models using 
logistic regression and conducted receiver operator characteristic (ROC) curve 
analysis using virological failure outcomes and predicted probabilities from the 
logistic model. We used the ROC curve to get optimum cut-off points that give the 
best trade-off between sensitivity and specificity and area under curve (AUC) as a 
measure of predictive power, for the two self-reported measures of adherence.  ROC 
models with two different ways of summarizing the results were employed to 
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estimate the AUC, sensitivity, specificity and cut-off points. In the first method, we 
estimated the AUC using parametric estimation. We also generated graphical 
sensitivity and specificity versus probability cut-off. The graph was used to get the 
best trade-off (cut-off point) to estimate sensitivity and specificity. Method two 
involved the non-parametric estimation of the ROC since the independent variables 
(self-reported measures) did not meet the assumption of following a normal 
distribution. We generated the ROC points by using possible outcomes of the viral 
load test result and tabulated the calculated sensitivities and specificities for each of 
the possible cut-off points including the area under the curve. The predictive 
accuracy of the two models was evaluated by considering the model with the largest 
AUC with the best sensitivity and specificity. Since neither of the adherence 
measures performed better than the other, both were used in objective 2b 
Objective 2a: In order to find factors associated with virological failure, both 
univariable and multivariable logistic regression models were fitted. To take into 
consideration the effect of the clustering of participants, survey robust estimation of 
the standard errors were used for both univariable and multivariable regression 
models. The survey estimation was done taking into account the sampling design, 
namely stratification and clustering. We decided to use a liberal P-value of 0.20 in a 
univariable analysis as a screening requirement to include variables in the 
multivariable model with the exception of study arm. Study arm as a design variable 
was automatically included in all models. We then sequentially omitted variables 
which were not statistically significant at the 5% level in the multivariable analysis to 
produce a final model of variables associated with virological failure (this principle 
was also used in objective 2b). Goodness of fit was assessed for the adjusted 
model.  
Objective 2b (Tobit model): In this objective, we investigated factors associated 
with self-reported adherence measurement scores.  First, univariable Tobit analysis 
was done and then a final model which included significant predictors of virological 
failure as well as those from the Tobit model. In order to assess prediction of self-
reported measures, we fitted Tobit regression models.  Tobit regression models 
(sometimes referred to as censored regression models) were initially developed by 
Tobin (1958) and are used when the outcome variable is constrained to take a 
certain range of values by having either an upper limit or a lower limit or both. The 
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constraint is defined as either left or right censoring (censoring from below/lower limit 
and above/upper limit respectively) (Jeffrey, 2013). In our case, self-reported 
adherence measures were constrained to lie between a lower limit of 0 and an upper 
limit of 100% and therefore, most of our participants were censored at the upper 
limit. In the Tobit regression model, the variable y can be regarded as a latent or 
unobservable dependent variable. The coefficients β assist in determining the 
relation between y and the independent variables xi in the same way as in ordinary 
least squares regression models.  Random fluctuations in the relationship between y 
and xi are captured by the “normally distributed error term” ui. We can therefore 
interpret the coefficients of the Tobit regression model in the same way we would for 
ordinary least squares regression.  
y= βxi + ui, ui ~ N (0, σ
2
) 
When fitting the Tobit regression models we used robust survey estimation methods 
to take into account the effects of clustering and stratification.  
Objective 3: Factors associated with virological failure and factors associated with 
self-reported adherence measurement scores were compared. The comparison 
considered whether the same factors that predicted virological failure were also 
associated with each of the two adherence measurements, and whether the 
estimated effects were consistent i.e. in the same direction. The “same direction” 
implies that if a risk factor predicted virological failure, we would expect the same 
variable to show a reduced self-reported adherence score, since poor adherence to 
ART is expected to lead to virological failure. 
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5. RESULTS 
 
Table 1 present the distribution of social, demographic and clinical characteristics of 
the participants according to study arm. The main Jinja trial was a cluster 
randomised trial where 22 clusters were randomised to either home based care or 
facility based care with a total of 1453 participants. A total of 1,276 participants 
qualified for this study. The home based care arm had a higher number of 
participants (754 patients) while 522 patients were in the clusters that were randomly 
assigned to the facility based care. The majority of the participants were women 
(914) compared to 362 men. 
The percentage distribution of men and women was similar between the two arms. 
Many of the participants had CD4 count of less than 50 cells/mm3 (n=351), and very 
few of the patients in the trial had CD4 count greater than 200 cells/mm3. The CD4 
cell count was not well balanced between the two arms, in particular a higher 
proportion of participants in the facility based arm had CD4 count 150-199 (29.50%) 
compared to those in the home based arm (21.75%). The majority of the participants 
were in the HIV WHO clinical stage II or III (Stage II: n= 595; Stage III: n=577).  The 
percentage distribution of participants in the HIV WHO clinical stages was similar 
between the two study arms. Many of the participants in the two arms were either 
single or married. The means of transport used by the majority of the participants to 
get to the TASO clinic was public taxi. About 95% of the study participants reported 
that adherence reminder tools were very useful. A large proportion of the participants 
reported reaching primary school education (n=713) and few reached tertiary level. 
The proportion of individuals without any formal education in the home based care 
(18.70%) was higher than in facility based care (13.60%).  
The median age and BMI were similar between the study arms. The overall median 
age of the patients was 38 years (IQR 32.0-44.0), and that of BMI at enrolment was 
21.8 kg/m2 (IQR 19.1-23.6).  The time taken to reach clinic and CD4 count has 
higher scores in facility based care than home based care. The median CD4 count of 
participants in the facility based care was 124 (IQR 46-169) compared to 105.5 (IQR 
41-167) in the home based care.  The overall median CD4 count was 116 (IQR 43.0-
167.0).  The large geographic area covered by the study meant that the time taken to 
reach the clinic would vary significantly among participants. The overall median time 
taken to get to the clinic was 1.0 hours (IQR 0.8-2.0).  
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Table 1: Socio-demographic and clinical characteristics by study arm 
Variables Facility  based care 
(n=522) 
Home based 
care (n=754) 
Total (n) 
Sex Male 164 (31.42%) 198 (26.26%) 362 
Female  358 (68.58%) 556 (73.74%) 914 
CD4 group <50 137 (26.25%) 214 (28.38%) 351 
50-99 66 (12.64%) 143 (18.97%) 209 
100-149 121 (23.18%) 158 (20.95%) 279 
150-199 154 (29.50%) 164 (21.75%) 318 
>200 44 (8.43%) 75 (9.95%) 119 
HIV WHO stages I 4 (0.77%) 14 (1.86%) 18 
II 236 (45.21%) 359 (47.61%) 595 
III 247 (47.31%) 330 (43.77%) 577 
IV 35 (6.70%) 51 (6.76%) 86 
Marital status Single 194 (37.16%) 262 (34.75%) 456 
Married 205 (39.27%) 313 (41.51%) 518 
Divorced 114 (21.84%) 168 (22.28%) 282 
Widowed 9 (1.72%) 11 (1.46%) 20 
Means of transport Walk 26 (4.98%) 26 (3.45%) 52 
Public Taxi 423 (81.03%) 638 (84.62%) 1061 
Boda/ Motorbike 16 (3.07%) 31 (4.11%) 47 
Boda Bicycle 29 (5.56%) 22 (2.92%) 51 
Others 28 (5.36%) 37 (4.91%) 65 
Usefulness of 
reminder 
Very useful  501 (97.09%) 719 (95.87%) 1220 
Moderately useful 14 (2.71%) 23 (3.07%) 37 
Not useful 1(0.19%) 8 (1.07%) 9 
 
 
Education  
None 71 (13.60%) 141 (18.70%) 212 
Primary 295 (56.51%) 418 (55.44%) 717 
Secondary 131 (25.10%) 170 (22.55%) 301 
Tertiary  25 (4.79%) 25 (3.32%) 50 
Age median (IQR)  38 (33-44) 37 (32-44) 38 (32-44) 
BMI median (IQR)  21 (19.2-23.4) 21.2 (19.2-23.8) 19.1 (21.8-23.6) 
CD4 median (IQR)  124 (46-169) 105.5 (41-166) 116 (43-167) 
Time  median (IQR)  1.25 (1-2) 1 (0.5-2) 1 (0.8-2.0) 
IQR= interquartile ranges  
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Table 2 describes the comparison of clinical characteristics of patients who were 
eligible for this secondary analysis and those who were excluded. A higher 
percentage of individuals excluded from our study were males compared to the 
group included in this analysis. The proportion of female participants was higher 
(71.63%) in the group included in our analysis than the group of individuals excluded 
(66.10%). The median age was 38 (32-44) for the patients included in this study 
similarly to the individuals excluded from our analysis 36 (30-43). Education status 
was well balanced between the groups. Majority of the individuals not included in our 
study were in the WHO stage III (54.24%) and IV (18.08%) compared to 45.22% and 
6.74% respectively for those included in this analysis. The median CD4 cell count for 
individual excluded was 37 (IQR 9-136), a very low value when compared to the 
participants included in our study 116 (IQR 43-167). A proportion of 52.54% of the 
excluded individuals were having CD4 cell count less than 50 cells/mm3 compared to 
27.51% of all the participants included in our study.  
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Table 2: Comparison of clinical characteristics of 1276 patients included in this study and 177 
enrolled in the main trail but excluded from this secondary analysis.  
Characteristics Total (n) 
 n = 1276 (%) n = 177 (%) 
Study arm    
Facility 522 (40.91%) 72 (40.68%) 
Home 754 (59.09%) 105 (59.32%) 
Sex   
Male 362 (28.37%) 60 (33.90%) 
Female 914 (71.63%) 117 (66.10%) 
Age median(IQR) 38 (32-44) 36 (30-43) 
Education    
None 212 (16.61%) 22 (12.43%) 
Primary  713 (55.88%) 103 (58.19%) 
Secondary  301 (23.59%) 48 (27.12%) 
Tertiary  50 (3.92%) 4 (2.26%) 
WHO stage   
I 18 (1.41%) 2 (1.13%) 
II 595 (46.63%) 47 (26.55%) 
III 577(45.22%) 96 (54.24%) 
IV 86 (6.74%) 32 (18.08%) 
CD4 count median (IQR) 116.0 (43.0-167.0) 37 (9-136) 
CD4 level   
<50 351 (27.51%) 93 (52.54%) 
50-99 209 (16.38%) 23 (12.99%) 
100-149 276 (21.87%) 27 (15.25%) 
150-199 318 (24.92%) 21 (11.86%) 
>200 119 (9.33%) 13 (7.34%) 
IQR = Interquartile ranges; n=1276 :Included in this study; n=177: Not included in this study 
 
In table 3 we present the self-reported adherence measures categorized into two 
groups. One group consisted of those who reported less than 100% and the other 
group was those who reported 100% adherence to see if any of those who reported 
100% adherence experienced virological failure at any time from month 12 onwards. 
The results revealed that 72 (13.87%) out of 519 participants who reported 100% 
adherence experienced virological failure for VAS. For adherence based on number 
of pills missed, 128 (12.80%) out of 1000 had virological failure.  
 
Table 3: Distribution of adherence measurement scores according to virological failure status. 
 Virological failure  
Self-reported measures No failure Failure Total  1276 (n) 
VAS    
<100% 632 (83.49%) 125 (16.51%) 757 
=100% 447 (86.13%) 72 (13.87%) 519 
Adherence score based on number of pills 
missed 
   
<100% 207 (75.00% 69 (25.00%) 276 
=100% 872 (87.20%) 128 (12.80%) 1000 
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Table 4 shows a description of adherence outcomes and treatment outcome. 
Assessment of virological failure at 12 months indicated that there were 1,079 
(86.56%) participants who didn’t have failure and 197 (15.44%) had virological 
failure. Self-reported adherence measures showed very high scores. The median 
VAS score was 98.8% (IQR 95.1-100) and median adherence score based on 
number of pills missed was 100% (IQR 100-100). The median number of pills taken 
per day was 4 (IQR 2-6). 
 
Table 4: Description of outcomes measurements 
Variables N (%) 
Treatment outcome: Virological failure  
No failure 1079 (84.56%) 
Failure 197 (15.44%) 
Adherence outcome: VAS  median(IQR) 98.8 (95.0-100.0) 
Adherence outcome: Number of pills missed  median (IQR) 100.00 (100.0-100.0) 
Number of pills taken per day  median (IQR) 4 (2-6) 
IQR: Interquartile ranges 
 
Objective 1 
The results of an analysis of the ability to predict virological failure by the two self-
reported adherence measures is shown in tables 5a and 5b. 
Table 5a: ROC analysis  for  adherence visual analogue score (VAS) 
ROC  Visual analogue score 
 Method 1 Method 2 
Optimal cut-offs 0.127 0.982 
Area under the curve 59.21% 40.00% 
Sensitivity 56.00% 45.18% 
Specificity  49.04% 43.73% 
 
Table 5a showed that the optimal cut-off point to balance sensitivity and specificity is 
0.127 and an area under the curve of about 60% using method 1 to analyse the 
ROC. The non-parametric analysis of the ROC using method 2 showed an optimal 
cut-off point of almost 100% with AUC at 40%. Method 1 predicted only 56% of the 
virological failures while the second method predicted only 45%.   
Table 5b : ROC analysis for adherence based on number of pills missed 
ROC  Adherence based on number of pills missed 
 Method 1 Method 2 
Optimal cut-offs 0.130 1.00 
AUC 60.00% 40.36% 
Sensitivity 35.50% 64.97% 
Specificity  81.06% 19.26% 
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For the adherence based on number of pills missed, the two ways of summarising 
the ROC analysis gave contrasting results (table 5b). The predictive capacity of 
method 1 was 60% while for the other was 40%.  Method 1 gave a cut-off point of 
0.130 in order to achieve the highest sensitivity (35.50%) and this gave a specificity 
of 81.66%, while method 2 gave a cut-off of 100% with sensitivity of almost 65% and 
a very low specificity of 19%.  Therefore prediction of participants with virological 
failure showed that adherence based on number of pills missed  only predicted 36% 
for method 1 and 64.97% for the other method. The ROC analyses showed some 
similarities and differences between the two adherence measures. The AUC’s were 
similar but sensitivity and specificity were different.  
Objective 2a 
Table 6 shows the results of the univariable analysis using robust survey estimation 
to predict possible risk factors associated with virological failure. In this objective, we 
first investigated whether the effect of CD4 counts on virological failure would be 
assessed as linear or non-linear. We used a linear term to model the effect of CD4 
count, since there was no evidence of non-linearity. The majority of the variables 
were not associated with virological failure.  Using a liberal p-value of 0.20 to screen 
for variables, age, sex, and usefulness of ART reminders and CD4 counts were 
confirmed statistically significant.  Other than the significant variables, time taken to 
reach clinic was the only variable to have a p value less than the liberal value of 
0.20.  
The proportion of virological failure between the study arms was very similar. A 
higher proportion of males (20%) experienced virological failure than females (14%). 
Participants who were widows had the highest proportion of virological failure 
followed by those who were single. The participants with secondary school education 
had the highest proportion of virological failure compared to other education status. 
A large proportion of those who had virological failure used Motorbike boda to get to 
the ART clinic compared to participants who used other means of transport. The 
proportion of virological failure was low in participants who reported use of 
adherence reminder as very useful (14%) compared to those who reported reminder 
as moderately useful (46%) and not useful (67%). A relatively higher proportion of 
participants diagnosed with WHO clinical stage II and III have experienced virological 
than participants in other stages of the disease progression. 
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Table 6:  Assessment of the association between factors and virological failure: Univariable 
model 
Factors  Levels Total n (%) OR  P values 95% CI 
Study arm Facility   522 (15.33%) 1.00 (ref)    
 Home 754 (15.52%) 1.01 0.941 0.679 1.515 
Sex Males 362 (19.61%)     
 Females 914 (13.79%) 0.66 0.009 0.479 0.895 
Age    0.96 0.004 0.940 0.987 
Marital status Single 456 (17.54%) 1.00 (ref) 0.921*   
 Married  518 (12.74%) 0.69  0.454 1.036 
 Divorced 282 (13.60%) 0.87  0.537 1.405 
 Widowed 20 (35.00%) 2.25  0.876 7.308 
Education None 212 (16.04%) 1.18  0.772 1.733 
 Primary 717 (14.17%) 1.00 (ref) 0.592*   
 Secondary 301 (18.60%) 1.385   0.994 
 Tertiary  50 (12.00%) 0.826  0.368 1.850 
Means of transport Walk 52 (11.54%) 0.70  0.296 1.668 
 Public taxi 1061 (15.65%) 1.00 (Ref) 0.881*   
 Motorbike 
boda 
47 (19.15%) 1.28  0.637 2.558 
 Bicycle boda 51 (13.73%) 0.86  0.528 1.392 
 Other 65 (13.85%) 0.86  0.455 1.647 
Time taken to reach 
clinic  
  1.16 0.073 0.986 1.358 
Usefulness of 
reminder 
Very useful 1220 (14.04%) 1.00 (ref) 0.001*   
 Moderately 
useful 
37 (45.95%) 5.87  2.535 13.613 
 Not useful 9 (66.67%) 12.59  2.836 55.865 
WHO  clinical stage I 18 (11.11%) 0.61 0.491* 0.145 2.263 
 II 595 (16.97%) 1.00 (ref)  0.076*  
 III 577 (14.90%) 0.86  0.614 1.194 
 IV 86 (9.30%) 0.50  2.338 1.076 
CD4 Per 25  
cell/mm3 
 0.94 0.010 0.893 0.984 
BMI Per 5 kg/m3  0.93 0.491 0.761 1.142 
*Overall p value; CI: Confidence interval; n (%): Total number of participants (percentage of 
participants with virological failure; OR: Odds ratio 
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Table 7 indicates factors that were significantly associated with virological failure. Study arm 
and CD4 cell count were not statistically significantly associated with virological failure. 
Table 7: Factors that are significantly associated with virological failure. Multivariable 
analysis 
Factors  Odds Ratio P values 95%  CI 
Study arm     
Facility  1.00 (ref)    
Home 1.05 0.807 0.700 1.579 
Sex     
Males 1.00 (ref)    
Females  0.70 0.032 0.507 0.967 
Age  0.95 0.001 0.930 0.980 
Usefulness of reminder  0.001*   
Very useful  1.00 (ref)    
Moderately 5.28  2.311 12.071 
Not useful  8.54  1.721 42.413 
Time taken to reach clinic 1.15 0.095 0.974 1.361 
CD4 per 25 cells/mm
3 
0.96 0.175 0.918 1.016 
CI = Confidence Interval  *Overall p value 
 
Table 8 shows the final model assessment of factors associated with virological 
failure after fitting logistic regression models using the survey analysis approach to 
adjust for clustering. A Hosmer-Lemeshow test showed no evidence of lack of fit in 
the model (p=0.933). Participants who were in the home based care arm had about 
7% higher odds of experiencing a failure compared to the facility care but the 
difference was not statistically significant. 
Female participants and older participants were less likely to experience failure.  
Patients who reported finding the use of adherence reminders only moderately 
useful and not useful at all were more likely to experience virological failure 
compared to those who found the reminders very useful. The odds of having 
virological failure among female participants was about 0.70 times that of males 
(95% CI: 0.485, 0.968; p=0.033). The chances of having virological failure was also 
found to decrease by 5% as participants get older by one year (95% CI: 0.928, 
0.979;  p=0.001). 
Overall, usefulness of adherence reminder was associated with virological failure 
(p=0.001). Participants who responded that usefulness of reminders were only 
moderate or not useful at all had about 6 and 9 times increased odds of developing 
virological failure respectively compared to those who found it very useful   
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Table 8: Odds ratios for association of factors with virological failure. Final  model  
Factors  Odds Ratio P values 95% Confidence Interval 
Study arm     
Facility 1.00 (Ref)    
Home 1.07 0.852 0.690 1.560 
Sex     
Male 1.00 (Ref)    
Female 0.68 0.033 0.485 0.968 
Age 0.95 0.001 0.928 0.979 
Usefulness of reminder  0.001*   
Very useful 1.00 (Ref)    
Moderately  5.65  2.472 12.915 
Not useful 8.88  1.828 43.108 
*Overall p value; Goodness of fit = 0.933 
 
 
Objective 2b 
Figures 2 to 4 show a graphical representation of the self-reported adherence of 
participants. The graphs indicate that the average self-reported adherence score by 
the study participants was estimated to be about 95% with the majority reporting 
100% adherence to ART. 
 
Figure 2: Distribution of adherence score based on VAS (%). The graph shows 
majority of the participants have reported VAS adherence score between 80 and 
100%.  
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Figure 3 Highlights excess number of participants with VAS score equal = 100%. 
Due to continuous nature of the scores, most values are unique in the dataset. The 
height of the bar where VAS score = 100% when compared to other bars shows that 
the vast majority of  participants have reported 100% adherence 
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Figure 4: Distribution of adherence score based on the number of pills missed (%). It 
shows there were more participants with adherence based on number of pills missed 
score reported 100%.  
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Figure 5 indicates the excess are participants where adherence score based on 
number of pills missed is equal to 100%. Due to continuous nature of adherence 
based on number of pills missed, most values are unique in the dataset. The height 
of the bar where adherence based on number of pills missed = 100% when 
compared to other bars shows the excess (too many) participants with the 100% 
value. 
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Visual analogue scale 
In this objective, we fitted univariable Tobit models, using robust survey estimators, 
to find factors associated with VAS. Table 9 shows the results of a univariable 
analysis to assess possible risk factors associated with VAS.  Here we also used a 
liberal p value (P=0.20) as a cut-off to consider variables for inclusion into the final 
model, the same principle was applied to adherence based on number of pills 
missed. Variables including education, time taken to reach clinic and usefulness of 
reminder have P-values less than 0.20. 
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Table 9:  Assessment of the association between factors and VAS: Univariable model 
Factors  Levels Coeff  P values 95% Confidence interval 
Study arm Facility  1.00 (ref)    
 Home 0.792 0.408 -1.128 2.714 
Sex Males 1.00 (ref)    
 Females 2.822 0.014 0.597 5.048 
Age  -0.026 0.556 -0.115 0.063 
Marital status Single 1.00 (ref) 0.006*   
 Married  2.516  0.223 4.809 
 Divorced 2.504  0.303 4.705 
 Widowed 5.447  -4.444 12.339 
Education None 0.763  -1.922 3.449 
 Primary 1.00 (ref) 0.107*   
 Secondary -1.794  -3.742 0.153 
 Tertiary  -2.778  -8.972 3.414 
Means of transport Walk -0.97  -5.505 3.106 
 Public taxi 1.00 (Ref) 0.297*   
 Motorbike boda -0.223  -4.060 3.613 
 Bicycle boda 1.508  -2.251 5.268 
 Other -4.012  -9.906 1.882 
Time taken to reach 
clinic 
 0.458 0.193 -0.241 1.158 
Usefulness of 
reminder 
Very useful 1.00 (ref) 0.135*   
 Moderately 
useful 
-6.504  -14.376 1.367 
 Not useful -1.611  -13.404 10.180 
WHO  clinical stage I -7.652  -20.950 5.645 
 II 1.00 (ref) 0.640*   
 III -1.439  -3.921 1.043 
 IV 3.439  0.224 7.156 
CD4 count Per 25 
cells/mm
3 
-0.060 0.727 -0.407 0.286 
BMI Per 5 kg/m
3 
-0.092 0.834 -o.980 0.795 
*Overall p value 
 
In table 10, we ran Tobit models with robust survey estimation to see how 
significantly associated factors and factors that met the liberal p-value for inclusion 
would predict VAS. The results indicated that study arm, sex, marital status, 
usefulness of reminder and education were not statistically significantly associated 
with VAS. Time taken to reach clinic showed a marginally significant relationship with 
VAS. 
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Table 10: Factors that  were significantly associated with VAS: Multivariable model 
Factors   Coefficients P values [95% Confidence interval 
Study arm      
Facility  1.00 (ref)    
Home  0.401 0.573 -1.027 1.830 
Sex     
Male 1.00 (ref)    
Female 1.206 0.126 -0.357 2.770 
Marital status     
Single 1.00 (ref) 0.070*   
Married 1.732  -0.274 3.739 
Divorced 1.422  -0.483 3.327 
Widowed 5.167  -1.296 11.631 
Usefulness of reminder     
Very useful 1.00 (ref) 0.154*   
Moderately useful -6.691  -14.036 0.654 
Not useful  -0.718  -12.193 10.756 
Time taken to reach 
clinic 
0.598 0.055 -0.013 1.209 
Education      
None 1.502  -4.331 3.437 
Primary  1.00 (ref) 0.121*   
Secondary  -0.918  -2.569 0.731 
Tertiary  0.941  -1.801 3.683 
* overall p value 
 
Table 11 is the final model. Factors that were significantly associated with virological 
failure were included into the final model, since the interest of our study was to 
compare self-reported adherence with HIV viral load testing. The finding indicated 
that only sex was significantly predictive of visual analogue score while time taken to 
reach clinic showed a marginally significant effect. The visual analogue score was 2 
points higher among female participants than males (coefficient: 2.218; 95% CI 
0.681, 3.755; p=0.006).  Time taken to reach clinic showed a marginally significant 
association with VAS. A unit increase in time taken to reach the clinic would increase 
VAS by 0.606 points (95% CI: -0.020, 1.233).  The rest of the predictors of virological 
failure showed no association with visual analogue score.      
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Table 11: Prediction of VAS using factors associated with virological failure and  factors 
associated with VAS: Final model analysis 
Factors  Coefficients   P Values  95% Confidence Interval 
Study arm     
Facility  1.00 (ref)    
Home  0.480 0.507 -0.974 1.936 
Sex     
Males 1.00 (ref)    
Females 2.218 0.006 0.681 3.755 
Age  -0.006 0.868 -0.086 0.073 
Usefulness of Reminder  0.163*   
Very useful 1.00 (ref)    
Moderately useful  -6.244  -13.809 1.320 
Not useful -0.946  -12.777 10.885 
Time taken to reach 
clinic 
0.606 0.058 -0.020 1.233 
 * = Overall p value 
 
Adherence based on number of pills missed 
Self-reported adherence based on the number of pills missed was modelled using 
Tobit analysis with robust survey estimation.  Univariable analysis was conducted to 
screen significantly associated variables, the same principles applied in VAS 
analysis was also used for adherence based on the number of pills missed (table 
12). The results showed that only the study arm was associated with adherence 
based on number of pills missed, while usefulness of reminders was marginally 
significant (p=0.08).  
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Table 12:  Assessment of the association between factors and adherence based on number 
of pills missed: Univariable model 
Factors  Levels Coeff  P values 95% Confidence interval 
Study arm Facility  1.00 (ref)     
 Home 15.143 <0.001 8.719 21.566 
Sex Males 1 (ref)     
 Females 1.80 0.510 -3.695 7.304 
Age  -0.017 0.926 -0.403 0.368 
Marital status Single 1.00 (ref)   0.789*   
 Married  0.2114  -5.489 5.912 
 Divorced -0.303  -7.659 7.052 
 Widowed -5.788  -24.298 12.721 
Education None 4.357  -3.406 12.120 
 Primary 1.00 (ref)  0.810*   
 Secondary 1.435  -5.017 7.888 
 Tertiary  2.389  -18.169 22.928 
Means of transport Walk -6.637  -18.518 5.243 
 Public taxi 1.00 (Ref)  0.409*   
 Motorbike boda -4.427  -18.622 15.767 
 Bicycle boda 1.939  -9.055 12.934 
 Other -10.544  -25.675 4.586 
Time taken to reach 
clinic 
 -1.827 0.213 -4.749 1.095 
Usefulness of 
reminder 
Very useful 1.00 (ref)  0.080*   
 Moderately 
useful 
-18.581  -34.987 -2.176 
 Not useful 2.218  -37.378 41.815 
WHO  clinical stage I 0.024  -39.857 39.907 
 II 1.00 (ref)  0.982*   
 III -2.609  -11.246 6.027 
 IV 7.419  -5.105 19.944 
CD4 Per 25 
cells/mm
3 
-0.330  -1.286 0.653 
BMI/25 Per 5 kg/m
3 
-1.094 0.452 -4.009 1.821 
*Overall p value 
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Table 13 shows multivariable model for variables that were selected from table 10.  
Both study arm and the usefulness of reminders were statistically significantly 
associated with adherence based on number of pills missed.  
Table 13: Factors that  were significantly associated with adherence based on number of pills 
missed: Multivariable model 
Factors  Coeff. P>t 95% Confidence interval 
Study arm     
Facility     
Home 12.873 0.001 7.500 18.246 
Usefulness of reminder  0.035   
Very useful  1.00 (ref)    
Moderately useful -19.247  -35.099 -3.395 
Not useful  -2.588  -42.052 36.874 
    
Table 14 is a final model incorporating factors associated with virological failure 
including and those associated with number of pills missed. Participants’ sex and 
age at baseline were not statistically significantly associated with adherence based 
on number of pills missed.  Both study arm and the usefulness of reminders were 
statistically significantly associated with adherence based on number of pills missed. 
Patients who were getting their ART from home had 13% higher predicted 
adherence as measured by the reported number of pills missed than those who were 
using facility based care for treatment. (Coefficient: 12.921; 95% CI: 7.887, 17.954 
and p = 0.001). The overall effect of usefulness of reminder was significant 
(p=0.036). Those who reported usefulness of reminder as only moderately useful 
had scores of about 20% lower than the scores of those who found reminders very 
useful. 
Table 14: Prediction of adherence based on number of pills missed using factors associated with 
virological failure and  factors associated with VAS: Final model analysis 
     
Factors Coefficient P value 95% Confidence interval 
Study arm     
Facility 1.00 (Ref)    
Home 12.921 0.001 7.887 17.954 
Sex     
Male 1.00 (Ref)    
Female  -0.391 0.858 -4.813 4.030 
Age 0.016 0.915 -0.289 0.321 
Usefulness of reminder  0.036*   
Very useful 1.00 (Ref)    
Moderately useful -19.310  -35.557 -3.064 
Useful  -2.688  -43.040 37.663 
*Overall p value 
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Objective 3:  
Table 15 summarises the comparison of the prediction of self-reported measures in 
terms of the factors that were associated with virological failure. Correct direction of 
the prediction was that if a participant showed odds of experiencing of virological 
failure, then the same person should have also reported lower self-reported 
adherence score. 
Table 15: Comparison between predictors of virological failure and self-reported adherence 
scores 
Factors  Virological failure VAS Number of pills 
missed 
 Odds ratio P value Coefficient P value Coefficient  P value  
Study arm       
Facility  1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Home  1.07 0.852 0.480 0.507 12.921 0.001 
Sex       
Male 1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Female 0.68 0.033 2.218 0.006 -0.391 0.858 
Age 0.95 0.001 -0.006 0.868 0.016 0.915 
Usefulness of reminder  0.001*  0.163*  0.036* 
Very useful  1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Moderately useful 5.65  -6.244  -19.310  
Not useful 8.88  -0.946  -2.688  
Time taken to reach 
clinic 
- - 0.606 0.058 - - 
*overall p value 
 
Overall, no single factor was associated with all three outcomes although sex and 
usefulness of reminders were associated with virological failure and one of the self-
reported adherence measures. Participants in the home-based care arm had 
significantly better adherence by pill report than those in the facility based arm. 
There was no evidence that study arm was associated with virological failure and 
also no evidence that study arm was associated with the VAS adherence measure. 
Patients’ sex showed same predictive direction with virological failure less likely for 
females and VAS higher for females, but lower for females using adherence based 
on number the pills missed. A similar finding was observed with age. Only the 
usefulness of reminders showed the same direction of prediction, that is to say, 
virological failure increased among those participants who found usefulness of 
reminders as moderate, the same patients also reported decreased self-reported 
scores. However, usefulness of reminder was not significantly associated with the 
VAS.  Time taken to reach clinic showed a marginally significant relationship with 
VAS but it was not associated with other 2 outcomes.  
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6. DISCUSSION 
The aims of this study were to assess two self-reported measures of adherence and 
also find factors associated with adherence.  
Our summary measure indicated that median score for VAS and adherence based 
on number of pills missed was 98 and 100% respectively which was above WHO 
recommended 95% adherence expectation for people under ART medication (Stone 
et al., 2001).  Despite having very high adherence scores, some patients who 
reported an adherence rate of 100% in our study still experienced virological failure, 
with an average of 14% of the participants who reported 100% adherence 
experiencing virological failure. Similarly, another study observed about 19% of 
those who reported 100% adherence to treatment having detectable virological 
failure (Côté et al., 2015, Dobbels et al., 2010). This finding tends to answer the 
dilemma posited by Wu et al. (2014) which questioned if self-reported measures, 
which tend towards “over-adherence”, can be used as a surrogate marker for 
virological failure.  Description of social and demographic and clinical characteristics 
by study arm showed a higher number of participants in home based care than 
facility based care. This finding is similar to that main paper of this study which also 
found that higher number of participants described by demographic and clinical 
character is in home based care (Jaffar et al, 2010). Percentage comparison 
between the arms was similar except for CD4 count which showed a lower median 
CD4 count in the home based care than in the facility based care, which could be 
due to chance. We also observed that the median CD4 count for individuals 
excluded from our study was lower than for those included. This difference in median 
CD4 count could be that the patients with very low CD4 counts were more likely to 
die before the 12 month follow-up visit, hence they were more likely to be excluded.  
For objective one, we compared two self-reported measures of adherence by 
assessing how well each predicts virological failure. We used two ROC methods 
which gave different assessment of the predictive ability of self-reported measures. 
The first ROC method was a parametric estimation of AUC and graphical generation 
of sensitivity and specificity versus probability cut-off while the second method 
employed a non-parametric version which generated possible outcomes of viral load 
and tabulated calculated sensitivities and specificity for each cut-off point including 
AUC.  A ROC curve is a common diagnostic method used in epidemiology to check 
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how well a marker discriminates between two disease states (Swets, 1986, Metz, 
1978). In the case of our study, we were discriminating between having virological 
failure or no virological failure. Different criteria have been employed to summarize 
ROC results (Swets, 1979, Hanley and McNeil, 1982, Kramer, 1988). Based on 
these principles, we used AUC, sensitivity and specificity to evaluate the two self-
reported measures in prediction of virological failure.  Looking at AUC, we found that 
the two ROC methods give different results. Method 1 showed that the AUC was 
about 60% for both self-reported adherence measures, while method 2 had 40%. An 
AUC estimates the predicative power of the self-report measures in determining 
patients with virological failure. A perfect AUC is equal to 1 meaning that in our case, 
the adherence measures should be able to accurately differentiate between 
participants with virological failure and those without virological failure and an AUC of 
0.5 is by chance. Our results indicated that the two methods are not good predictors 
of virological failure especially since method 2 which is an empirical ROC method, 
had less than 50% AUC, meaning the adherence rate performed worse than chance 
(Hanley and McNeil, 1982). Both VAS and number of pills missed showed lower 
predicative ability of participants with virological failure by the two ROC methods.   
The ability of the adherence measures was based on how well they predict 
virological failure. This low prediction of the participants with virological failure 
indicated that self-reported adherence does not adequately predict failure. Available 
studies compared adherence measurement methods such as pharmacy refill, 
electronic monitoring and self-report in prediction of virological failure. Our finding is 
consistent with these comparative studies.  For example,  a study conducted in 
Tanzania which showed that self-reported adherence was not a good predicator of 
virological failure as it was outperformed by pharmacy refill measures (Sangeda et 
al., 2014). Another comparison of adherence measures also revealed that self-
reported adherence is less sensitive as the chances of having virological failure was 
higher than using electronically monitored adherence (Arnsten et al., 2001a). Our 
results differ from  the finding of a study which reported that self-reported measures 
are valid when compared with viral load count values (Godin et al., 2003). Our 
results showed that self-reported measures cannot be used as a substitute for viral 
load measurement to determine virological failure because they predict virological 
failure poorly. Despite its widely known low cost and ease of operation, our findings 
have shown that self-reported adherence measures over-estimate actual adherence.  
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For objective 2a we investigated the risk factors associated with virological failure. 
Since a binary outcome was used in objective 1, we decided to also employ the 
same binary outcome for finding factors associated with virological failure in this 
objective. An alternative approach to the analysis would have been to use a time to 
event analysis to analyse the time to virological failure, but this was not done in this 
analysis.  
Our findings showed that the risk factors associated with virological failure were sex; 
age, and usefulness of adherence reminders. Female participants were at a lower 
risk of having virological failure, indicating that females adhere better to ART 
treatment than males. It is not known why females experience less virological failure 
than males. We think that women’s chance of experiencing lower virological failure 
than men could be due to being more careful about their personal wellbeing than 
males. Another possible explanation could be that women obey medication 
instructions much better.  In Africa, one possible reason could be that men leave 
their home to work while women remain in the home settings which might lead to 
missed doses in the case of men. A similar study conducted in Burkina Faso also 
showed susceptibility to virological failure was higher among men than women  
(Penot et al., 2014). In contrast, a study conducted in Brazil showed that chances of 
poor adherence are much higher among females than males (de Fatima Bonolo et 
al., 2013). These conflicting results may be due to differences in adherence 
measurement tools and number of male and female participants enrolled. Gender 
effects might also vary between different cultures. 
Another result showed that older people were at a lower risk of virological failure. We 
suggested that lower risk of virological failure in older participants might be due to 
their understanding or awareness of the HIV/AIDS effects. Our finding is consistent 
with a study conducted in Uganda which found that patients who were older than 35 
years had 50% chance of having decreased virological failure compared to those 
who were below 35 years of age (Ahoua et al., 2009). The finding is also consistent 
with a study in Swaziland, Jobanputra et al. (2015) also confirmed that younger age 
group were more likely to have detectable viral load (virological failure) than adults. 
However some studies have contrasting results, for instance studies by Kilaru et al. 
(2006)  and Moore et al. (2005) reported that participants of advanced age are at risk 
of treatment failure. Our finding can be attributed to the difference in knowledge 
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about the importance of ART and the lack of social support among the young 
compared to the older population.  
We found that the odds of virological failure tended to increase by 6 fold among 
participants who found reminders as only moderately useful compared to participants 
who found reminders very useful, while participants who didn’t think adherence 
reminders were useful had a 9-fold increased probability of virological failure. Typical 
example of adherence reminders could include timers/alarm and adherence support 
mechanism from family members.  It could be argued that those who do not use 
reminders tend to forget taking medication in a timely fashion; this could lead to 
virological failure. The finding is supported by studies which found that forgetfulness 
is an important indicator of increasing virological failure (Watt et al., 2010, Mitiku et 
al., 2013, Shumba et al., 2013). Forgetfulness is confirmed by our study which stated 
that the use of a personal adherence reminder tool is an important part of ART 
administration as people who found use of reminders as useful experienced 
significantly decreased rate of virological failure compared to those who did not use 
reminders.  Our findings support the fact that further studies in Africa also found 
forgetfulness is the main factor for non-adherence (Mthembu and Van Wyk, 2014, 
Odili et al., 2016). The use of adherence reminders is an important intervention to 
ensure adequate adherence to drug regimens. Failure to use reminders would make 
patients forget to take ART regimens. 
For objective 2b, we determined the factors associated with self-reported measures 
of adherence using Tobit modelling. The Tobit model was used because the data is 
constrained to fall between two points (0 and 100%) and the data thus did not meet 
the assumptions for linear regression.  From the Tobit model, females reported 
higher VAS adherence than males while study arm and usefulness of reminder were 
predictive of number of pills missed. There is gender disparity in access of ART and 
this could lead to better self-reported adherence reports among women than men. 
We also think that men might have poor access to HIV voluntary counselling and 
testing and ART clinics partly because of fear of stigmatization. Gender differences 
in access and adherence to ART may be related to several support services offered 
to women. For instance, in resource limited countries, there is increased maternal 
care comprising of mother to child HIV transmission programmes and counselling 
could have created such disparity between men and women (Braitstein et al., 2008). 
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Time taken to reach clinic was marginally significantly related to reporting VAS. Our 
study showed that participants who took a longer time had higher VAS score. Ideally, 
longer time taken to reach clinic means the distance to the clinic is far but some 
studies showed that the long distance to the ART clinic decreases adherence which 
is contrary to our findings (Mills et al., 2006a). We think that participants might feel 
they have worked so hard to get the medication by spending many hours to go to the 
clinic to get ART and this might have made them adhere well to the drugs. Also time 
taken to reach clinic might vary significantly between home based care and facility 
based care since those in the home based visited the clinic much less often. Patients 
who  considered the usefulness of reminders as being only moderately useful had 
lower chances of high reporting scores for adherence based on number of pills 
missed than those who found it very useful. This is consistent with a study which 
found that adherence was higher among groups utilising reminder tools for uptake of 
ART doses than people who did not (Fenerty et al., 2012). Use of adherence 
reminders might have resulted in consistent uptake of ART which led to better self-
reported adherence measurement scores. Patients receiving home based care of 
ART had a higher predicted value of adherence based on number of pills missed. 
Bringing HIV treatment services closer to the people or to the community might have 
importantly reduce the burden and cost of travelling to clinics to receive treatment 
thus such plans might have contributed  to better chances of reporting adherence. 
Elsewhere in Brazil, similar comparison showed that participants from home based 
care reported better adherence than facility care (Gupta et al., 2005).  
For objective 3, we directly compared results from objectives 2a and 2b. We could 
not find any particular variable that was associated with all three of the adherence 
measures. We observed that sex had the same direction of prediction of virological 
failure and VAS; the same was confirmed with usefulness of adherence and study 
arm in reporting adherence based on number of pills missed scores.  We suggest 
that these findings support the assertion from objective one which confirmed self-
reported method of evaluating ART adherence is not as good as viral load count.  
Strength and limitations  
The strengths of our study in the context of a randomised controlled trial are that our 
study had relatively large sample size; little missing data and rigorous data collection 
methods were employed.  On the other hand, there are a number of limitations in this 
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study. The disparity in CD4 count between the study arms may be due to the 
weakness of the study design in achieving similarity through randomisation (Jaffar et 
al, 1999). One limitation of our study is that we used only two of the self-reported 
measures of adherence; there might be other measures of adherence that are better 
at predicting virological failure. The number of participants we used in this analysis 
was more than the number used in the main trial. Participants who did not have any 
viral load measurements after 12 months, or had a single viral measurement 
between 500-1000 copies/ml, but not confirmatory measurement were included in 
this study. Such participants were regarded as not having experienced virological 
failure, as this is the reason why including them could result in some bias.  A liberal p 
value of <=0.20 in a univariable analysis was used to include variables in the 
multivariable analysis; some associations might have been missed if there was 
negative confounding. An alternative approach could have been used in this regard.  
Our results demonstrated there may be high social desirability bias where some 
participants tend to over-report adherence in order to be viewed favourably by the 
trial staff. This ultimately affects the ability of the self-reported adherence measures 
to correctly predict virological failure. We used only a 3-day period to measure 
adherence based on number of pills missed, with such an interval, it becomes 
difficult to group participants with better adherence over long period and those with 
better adherence maybe for just over short period of time yet they may be adhering 
poorly overall (Simoni et al., 2006b). As studies by Swets (1988) and Begg (1991) 
confirmed, our study used a single sensitivity and specificity value which was chosen 
by looking at cut-off points, thus such cut-off points is based on personal choice 
rather any reason or system. Some of our variables have very few individuals in 
some categories; this would affect the precision of the effect estimates and make it 
difficult to find statistical significance. The distribution of the adherence measures is 
extremely skewed; this might have affected the performance of the ROC curve in 
computing sensitivity and specificity.  
Conclusion and recommendation  
In conclusion, our study shows that self-reported measures are poor predictors of 
virological failure and therefore, are not good measures of ART adherence. We 
expected that self-reported adherence measures should be able to correctly predict 
at least 85% of patients with virological failure, but the measures only correctly 
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predicted between 35% to 65% of the participants with virological failure.  No risk 
factor was associated with all the adherence measurement methods. Study arm and 
usefulness of adherence reminder was associated with adherence based on number 
of pills missed. Measuring ART adherence is one of the most important components 
in the fight against HIV and AIDS.  Viral load testing should be highly encouraged 
even in resource limited settings. 
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8. APPENDICES  
8.1. APPENDIX 1 
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8.2. APPENDIX 2 
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8.3. Adherence questionnaire 
 
TASO/MRC/CDC ART DELIVERY RESEARCH PROGRAMME 
 
To be administered at a) 2, 6, 12, 18, 24, 30, 36 month routine visits, b) at any time a client presents with 
suspected treatment failure and c) at the unannounced home visit 6 months after recruitment.) 
 
Interviewer to read: 
We understand that many people on ART drugs find it difficult to take the drugs and often miss 
doses. We will not be surprised if you have missed lots of doses as well. We need to know how many 
doses you missed. The answers that you give shall not affect the services that you receive from TASO. 
 
Tukimanyi nti abantu bangi abamira eddagala lya ART kibakaluubirira okumira eddagala lino 
nebatayosaamu. Tekijja kutwewunyisa singa naawe oba wayosaamu okumira amakerenda agawerako. 
Kyetwagala kwekumanaya obungi bw’eddagala lyewakayosa okumira. Kino tekija kukosa mungeri 
yonna obuyambi bw’ofuna okuva mu TASO. 
 
SECTION 1. GENERAL 
      
1.0 Client ID Number 6 digits  STUDY_ID 10 
   
 
   
2.0 Today’s date dd / mm / yyyy  TDATE 20 
    
 
  
3.0 Which type of visit is this?  1-3 from codes below If 2,3 >> 5.0 VISTCAT 30 
 
 
1=scheduled routine visit (at 2, 6, 12, 18, 24, 30, 36 months),     2=client is unwell and has been referred or has self-
referred.     3=unannounced home visit by MRC 
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4.0 Interview round  1-7 from codes below IROUND 40 
 
 
     
1=2 monthly,      2=6 monthly,     3=12 monthly,      4=18 monthly,     5=24 monthly,     6=30 monthly,    7=36 monthly 
8=42 monthly,    9=48 monthly 
 
 
5.0 Has any of your ART medication changed in 
the last 6 months 
Amakerenda g’omira aga ART gaali 
gakyuseemu mu myezi mukaga egiyise?  
1 = yes, 2 = no  TCHANGE 50 
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SECTION 2. VISUAL ART ADHERENCE SCORE 
 
Interviewer to read: Please put a cross on the line below at the point showing your best guess about how much 
ART medication you have taken in the last 28 days:  
 
 0% means you have taken no ART drugs  
50% means you have taken half of your ART drugs  
100% means you have taken all your ART drugs. 
 
 
Tukusaba oteeke akasale kukasitaale kano wamanga akalaga w’olowooza nti wewasinga okulaga obungi 
bw’eddagala lya ART ly’omizze munaku abiri mumunaana (28) eziyise. 
 
Awasooka (0%) walaga nti tolina ddagala lyonna elya ART ly’omizze,  
Wakati (50%) walaga nti kuddagala elya ART lyolina okumira, omizeeko ebitundu ataano ku buli kikumi,  
Awaseembayo (100%) walaga nti eddagala elya ART ly’olina okumira, lyonna olimizze. 
 
 
          
0% 
 
10% 20% 30% 40% 50% 60% 70% 80% 90%          100% 
 
 
6.0 Visual score Read from above  VISUAL 60 
 
 
 
 
60 
 
SECTION 3. ART PILLS MISSED  
 
7.0 How many ART pills (tablets) do you take 
per day? 
Omira amakerenda ga ART ameka 
olunaku? 
Number of pills  NOPILLS 70 
      
8.0 Have you missed taking any of your ART 
pills in the last 3 days (excluding today)? 
Waliwo lwotamira amakerenda go aga 
ART munaku ssatu eziyise (ng’ogyeko 
olwaleero)? 
1 = yes, 2 = no  
 
 
IF 2 » 9.0 
ANYMISS3 80 
      
8.1 If yes 
Oba Ye 
How many ART pills did you miss 
yesterday? 
Amakerenda ameka aga ART 
g’otamize jjo? 
Number of pills  NOMISS3 90 
 
 
 
  
 
   
8.2  How many ART pills did you miss 
the day before yesterday? 
Amakerenda ameka aga ART 
g’otamira okwosa jjo? 
“  MISSM1 100 
       
8.3  How many ART pills did you miss 
day before that (3 days ago)? 
Amakerenda ameka aga ART 
g’otamira enaku ssatu eziyise 
(enaku ssatu eziyise)? 
“  MISSM3 110 
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9.0 How many ART pills have you missed in the 
last 2 weeks? 
Amakerenda ameka aga ART g’otamira 
sabiiti bbiri eziyise? 
Number of pills  MISSM14 120 
 
 
10.0 How many ART pills have you missed in the 
last 1-month? 
Amakerenda ameka aga ART g’otamira 
omwezi gumu oguyise? 
“  MISSM28 130 
 
 
11.0 When was the last time you missed your 
ART pill? 
Ddi lwewasembayo okwosa okumira 
amakerenda go aga ART? 
1-7 from list below IF 6 or 7 
 » 24.0 
LASTMISS 140 
      
 
1=today,   2=yesterday,   3=earlier this week,   4=last week,    5=less than a month ago,    6=more than a month ago,  7=have 
never missed taking my ART pill. 
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SECTION 4. REASONS FOR MISSING ART PILLS 
 
Interviewer to read: People may miss taking their medicines for various reasons. Here is a list of 
possible reasons why you may miss taking your medicines. In the last month, did you miss taking your 
medicines because of the following? 
 
Abantu boosa okumira eddagala lyabwe olw’ensonga emu oba endala. Wamanga waliwo ensonga 
zetulowooza nti zezimu kwezo. Mumwezi oguwedde, wayosa okumira eddagala lyo olw’ensonga 
zino?  
 
12.0 You were away from home 
Wali toliiwo awaka 
1=yes, 2=no  
 
If 2 » 13.0 
AWAYHOME 150 
 
 
     
12.1 If yes, how many times?  
Oba Ye, gyaali mirundi emeka? 
NAWAYHOME 160 
 
 
13.0 You simply forgot 
Werabira bwelabizi  
1=yes, 2=no  
 
 
If 2 » 14.0 
FORGOT 170 
      
13.1 If yes, how many times? 
Oba Ye, mirundi emeka? 
NFORGOT 180 
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14.0 You had too many pills to take and could 
not swallow all 
Wali olina empeke nyingi ez’okumira, 
nezikuyitirirako. 
1=yes, 2=no PILLBURDEN 
 
If 2 » 15.0        
190 
 
 
 
    
14.1 If yes, how many times? 
Oba Ye, gyali emirundi emeka? 
NPBURDEN 200 
 
 
15.0 You had fear of side effects (e.g. felt drug 
was toxic or harmful?) 
Watya ebiyinza okuva mukukozesa 
eddagala (tugeze ng’okulowooza nti liyinza 
okuba nga lyabulabe) 
1=yes, 2=no  
 
 
If 2 » 16.0 
SEFFECT 210 
   
 
 
15.1 If yes, how many times?  
Oba ye, gyali emirundi emeka? 
NFEARAE 220 
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16.0 You fell sick  
Walwala 
1=yes, 2=no FELLSICK 
 
 
If 2 » 17.0                
230 
     
16.1 If yes, how many times?  
Oba Ye, gyali emirundi emeka? 
 
 NFELLSICK 240 
 
 
    
17.0 You felt depressed/overwhelmed with issues 
of your illness 
Wawulira nga oli mweralikirivu nga 
ebikwata kubulwadde bw’olina 
bikuyitiriddeko 
 
1=yes, 2=no                FELTDEP 
 
 
 
If 2 » 18.0 
250 
 
     
17.1 If yes, how many times? 
 Oba Ye, gyali emirundi emeka? 
 
NFELTDEP 260 
 
 
18.0 You ran out of medicines 
Eddagala lyaggwawo 
 
 
1=yes, 2=no  
 
If 2 » 19.0                
RANOUT 270 
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18.1 If yes, how many times?  
Oba Ye, gyali emirundi emeka? 
 
 NRANOUT 280 
 
 
19.0 You felt good or better and did not see the 
need to take pills 
Wawulira ossuuse n’otalaba nsonga lwaki 
olina okumira amakerenda. 
 
1=yes, 2=no  
 
 
If 2 » 20.0  
FELTGOOD 290 
      
19.1 If yes, how many times? 
 Oba Ye, gyali emirundi emeka? 
 NFELTGOOD 300 
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20.0 You were advised by someone else to stop 
taking medicines 
Waliwo eyakuwa amagezi nti oleker’awo 
okumira amakerenda 
1=yes, 2=no  
 
If 2 » 21.0 
ONADVISE 310 
 
 
     
20.1 If yes, how many times?  
Oba Ye, gyali emirundi emeka? 
 NADVISE 320 
 
21.0 Did not want others to notice you taking 
drugs 
Wali toyagala balala kumanya nti omira 
amakerenda 
1=yes, 2=no  
 
If 2 » 22.0  
ONOTICE 330 
 
 
     
21.1 If yes, how many times?  
Oba Ye, gyali emirundi emeka? 
 NONOTICE 340 
 
 
     
22.0 Other reason (1) 
Ensonga endala (1) 
1=yes, 2=no  
 
If 2 » 24.0  
OTHER1 350 
 
 
 
 
     
22.1 Specify 
Nnyonnyola 
  XX 
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22.2 How many times?  
Emirundi emeka? 
 NOTHER1 360 
 
 
23.0 Other reason (2) 
Ensonga endala (2) 
1=yes, 2=no  
 
If 2 » 24.0 
OTHER2 370 
      
23.1 Specify 
Nnyonnyola 
  XX 
 
 
     
23.2 How many times?  
Emirundi emeka? 
 NOTHER2 380 
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SECTION 5. TIMING OF ART DOSES 
 
Interviewer to read: We understand that many people on ART find it difficult to take the drugs on 
time. We need to know how many doses you took within the time that you were advised by TASO.  
Tukimanyi nti abantu bangi abamira eddagala lya ART kibakaluubirira okumira eddagala ku 
budde bwalyo. Twagala kumanya obungi bw’eddagala lyomizze ku budde bwalyo nga TASO 
bweyakusomesa. 
 
24.0 What times in the day do you usually take 
your ART drugs: 
Bude kki mu lunaku bwotera okumira 
eddagala lyo erya ART? 
Write time using 24 hour clock (e.g. 
7pm should 1900) 
  
      
  Dose 1:  DOSET1 390 
      
  Dose 2:  DOSET2 400 
      
  Dose 3:  DOSET3 410 
 
 
25.0 In the last month, how many of your pills 
did you take within half an hour 
Mu mwezi oguwedde, amakerenda ameka  
aga ART gewamira mu kitundu ky’esaawa 
emu? 
Codes 1-6 from list 
below 
 TIME1 420 
 
 
     
26.0 In the last month, how many of your pills 
did you take within one hour  
Mu mwezi oguwedde, amakerenda ameka 
aga ART gwewamira mu saawa emu? 
Codes 1-6 from list 
below 
 TIME2 430 
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27.0 In the last month, how many of your pills 
did you take within two hours 
Mu mwezi oguwuedde, amakerenda ameka 
aga ART gewamira mu saawa bbiri? 
Codes 1-6 from list 
below 
 TIME3 440 
 
 
     
1=none,    2=very little,     3=less than half,     4=about half,      5=more than half,     6=nearly all or all 
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SECTION 6. ART ADHERENCE REMINDERS AND SUPPORT  
 
Interviewer to read: People taking their medicines on a daily basis have things that help remind them to take 
their drugs on time. In the last month, what has helped you personally, to take your drugs on time? 
Abantu abamira eddagala erya ART buli lunaku balina ebintu ebibajjukiza okurimirira mu budde. Mu mwezi 
oguwedde, kiki ekikuyambye ng’omuntu okumira eddagala lyo erya ART mu budde?  
 
 
 
28.0 Use of reminders (e.g. after brushing teeth, 
meal times) 
Okukozesa ebyeyambisibwa okujjukira 
(tugeze, nga wakamala okusenya, oba 
ebisera byemere) 
Codes 1-4 from list 
below 
 REMINDERS 450 
 
 
29.0 Monthly contact with TASO staff  
Okulabagana naba TASO Jinja buli mwezi 
“  MVISIT 460 
 
 
30.0 Support of medicine companion 
Okwewaayo kw’oyo eyeyama okkuyamba  
mu by’okumira  eddagala 
“  SCOMPANION 470 
 
 
31.0 Existence of personal adherence plan 
Entekateeka zewakola oleme kwerabira 
okumira eddagala lyo 
“  ADPLAN 480 
 
 
     
32.0 Morning/evening prayers 
Essaala z’okumakya n’akawungezi 
“  PRAYER 490 
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33.0 Desire to improve health, self drive 
Nze kenyinni okwagala okubeera omulamu 
“  DRIVEN 500 
 
 
     
34.0 Past experience with other medications 
Obumanyirivu bwennina mukumira 
eddagala edala 
“  PASTEXP 510 
 
 
     
35.0 Support from other household members 
Obuyambi bwenfuna okuva 
mub’ennyumba yange 
“  HSUPPORT 520 
 
1= very useful,     2 = moderately useful,      3 = not useful,     4 = not applicable 
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36.0 Other 
Ekirala… 
“  OTHER 530 
 
36.1 Specify 
Nnyonnyola 
 XX 
      
1= very useful,     2 = moderately useful,      3 = not useful,     4 = not applicable 
 
 
SECTION 7. ART DRUG SHARING 
 
37.0 Many times it is difficult when our children 
or others fall sick in the household. Have 
you ever shared your ART drugs with others 
who need it?  
Ebiseera ebisinga kiba kiseera kizibu  
abaana baffe oba abalala betubeera nabo 
bwebalwara. Wali ogabanyeeko  ku 
ddagala lyo erya  ART n’abo abalyetaaga? 
1=yes, 2=no  
 
 
 
 
 
If 2 » 38.0 
SHARED 540 
      
37.1 If YES, how many ART pills did you share in 
the last month? 
Oba Ye, wabawaako empeke meka eza ART 
mu mwezi oguwedde? 
Number of pills  NOSHARED 550 
 
38.0 Do any of your family members living with 
you need ART drugs but do not have them? 
Olina bobeera nabo abetaaga eddagala 
lya ART naye nga tebalifuna? 
1=yes, 2=no  ARTNEED 560 
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39.0 Are you under pressure to share your ART 
drugs with other people? 
Waliwo embeera yonna ekuwaliriza 
okugabana eddagala lyo erya ART 
n’abantu abalala bonna? 
1=yes, 2=no  
 
 
If 2 » 40 
PRESSURE 570 
      
39.1 If YES, from whom 
Oba ye, embeera eyo eva ku’ani? 
Code 1-8 from list 
below 
 WHOPRESS 580 
 
1=Spouse,   2=Parent,   3=Sibling,    4=Biological child,    5= Other relative,    6=Friend,    7=Neighbour,     8=Other  
      
39.2 If other, specify 
Oba balala, nnyonnyola 
XX 
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SECTION 8. MISCELLANEOUS QUESTIONS 
 
Please tell us how many times in the past month you did the following: 
Tukusaba otubuulire mirundi emeka mu mwezi oguwedde gyewakola bino wammanga: 
 
40.0 Saw your medicine companion for 
support/reminder? 
Okulaba oyo eyeyama okukuyamba 
okumira eddagala 
Codes 1-7 from list 
below 
NMEDICINE 590 
 
41.0 Drank alcohol 
Wanywa omwenge 
“  NALCOHOL 600 
 
42.0 Took drugs such as marijuana 
Okweyambisa ebiragalalagala nga enjaga 
“  NDRUGS 610 
 
 
     
43.0 Were away from home for at least one 
night 
Tewasula waka okumala olunaku lumu 
“  NAWAY 620 
      
44.0 Came to TASO Jinja for counseling 
Wajja ku TASO e Jinja okufuna 
okubudabudibwa 
“  NCOUNSEL 630 
 
45.0 Came to TASO Jinja or other clinic because 
you felt unwell 
Wajja ku TASO e Jinja oba ku ddwaliro 
eddala kubanga wali tewewulira bulungi 
“  NTREAT 640 
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46.0 Were admitted to hospital at Jinja or 
elsewhere for at least one night 
Walwala nebakuwa ekitanda mu dwaliro e 
Jinja oba mu dwaliro eddala lyonna 
okumala ekiro kimu 
“  NADMITTED 650 
 
 
     
1 = not once in the month,      2 = once in the month,     3 = 2-3 times a month,     4 = 4-8 times per month  
5 = 9-16 times per month,       6 = nearly every day,       7 = daily 
 
 
INTERVIEWER’S SIGNATURE  XX 
 
 
    
INTERVIEWER ID CODE 2 digit code  IPERSID 660 
 
 
    
DATE FORM COMPLETED dd / mm / yyyy  FDATE 670 
 
 
    
FORM SEQUENCE NUMBER 4 digits  FSEQID 680 
12/02/2005 08:04 
 
 
